News › Clinical Practice, Industry News, Patient Care

Sculptra and Restylane Deliver 9-Month Skin, Confidence Boost Post-medication Weight Loss

August 1, 2025

Galderma recently announced final nine-month results from its phase 4 clinical trial confirming that the combination of Sculptra and Restylane Lyft or Contour delivers sustained improvement in facial appearance and high patient satisfaction for individuals facing aesthetic changes due to medication-driven weight loss.

The results, said clinical trial investigator Michael Somenek, MD, represent an evolution in how the aesthetics field can holistically support patients through their weight loss journey, both physically and emotionally.

Read more at Dermatology Times >>

 

Become a member

Get the tools you need to succeed in the medical spa industry.

Related
    • Retatrutide Phase 3 Trial: Adults With Type 2 Diabetes Lost Average of 50 Pounds
    • Medical Marketing Whiz Recognized With Healthcare Digital Marketing Excellence Award
    • Allergan Presents Early Data on Skin Quality Treatments for Patients Taking Weight-Loss Medications
    • ValueCap Becomes Silver Vendor Affiliate with the American Med Spa Association
    • FDA Warning Letter Signals Increased Scrutiny of the Medical Necessity Exception for Compounded GLP-1s
Advertisement